Search details
1.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
N Engl J Med
; 375(18): 1738-1748, 2016 11 03.
Article
in English
| MEDLINE | ID: mdl-27717303
2.
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
BMC Cancer
; 19(1): 1032, 2019 Nov 01.
Article
in English
| MEDLINE | ID: mdl-31675952
3.
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
Breast Cancer Res Treat
; 171(1): 111-120, 2018 Aug.
Article
in English
| MEDLINE | ID: mdl-29744674
4.
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.
Eur Heart J
; 37(4): 412-22, 2016 Jan 21.
Article
in English
| MEDLINE | ID: mdl-26637834
5.
Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival.
Int J Hyperthermia
; 31(4): 386-95, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25811737
6.
Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy.
Support Care Cancer
; 22(10): 2851-9, 2014 Oct.
Article
in English
| MEDLINE | ID: mdl-24821365
7.
Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer.
Int J Hyperthermia
; 30(5): 285-94, 2014 Aug.
Article
in English
| MEDLINE | ID: mdl-25144817
8.
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
Breast Cancer Res Treat
; 137(2): 471-82, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-23239151
9.
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.
JAMA Netw Open
; 5(5): e2213070, 2022 05 02.
Article
in English
| MEDLINE | ID: mdl-35594047
10.
Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer.
JCO Precis Oncol
; 6(1): e2100321, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35721584
11.
Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.
Breast Cancer Res
; 13(3): R62, 2011 Jun 07.
Article
in English
| MEDLINE | ID: mdl-21672245
12.
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.
Breast Cancer Res
; 13(6): R125, 2011.
Article
in English
| MEDLINE | ID: mdl-22132754
13.
New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.
Cancer Invest
; 29(8): 533-41, 2011 Oct.
Article
in English
| MEDLINE | ID: mdl-21843051
14.
Safety of bevacizumab in patients with metastatic breast cancer.
Oncology
; 80(5-6): 314-25, 2011.
Article
in English
| MEDLINE | ID: mdl-21778772
15.
Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data.
Int J Hyperthermia
; 26(7): 612-7, 2010.
Article
in English
| MEDLINE | ID: mdl-20849256
16.
Hyperthermia for locally advanced breast cancer.
Int J Hyperthermia
; 26(7): 618-24, 2010.
Article
in English
| MEDLINE | ID: mdl-20849257
17.
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.
Clin Breast Cancer
; 20(2): 145-151.e2, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31558424
18.
DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study.
Int J Hyperthermia
; 25(6): 405-15, 2009.
Article
in English
| MEDLINE | ID: mdl-19657852
19.
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Target Oncol
; 14(1): 1-12, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30136059
20.
Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Target Oncol
; 14(1): 13, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30535552